Literature DB >> 8446717

Skin anatomy and antigen expression after burn wound closure with composite grafts of cultured skin cells and biopolymers.

S T Boyce1, D G Greenhalgh, R J Kagan, T Housinger, J M Sorrell, C P Childress, M Rieman, G D Warden.   

Abstract

Closure of large skin wounds (i.e., burns, congenital giant nevus, reconstruction of traumatic injury) with split-thickness skin grafts requires extensive harvesting of autologous skin. Composite grafts consisting of collagen-glycosaminoglycan (GAG) substrates populated with cultured dermal fibroblasts and epidermal keratinocytes were tested in a pilot study on full-thickness burn wounds of three patients as an alternative to split-thickness skin. Light microscopy and transmission electron microscopy showed regeneration of epidermal and dermal tissue by 2 weeks, with degradation of the collagen-GAG implant associated with low numbers of leukocytes, and deposition of new collagen by fibroblasts. Complete basement membrane, including anchoring fibrils and anchoring plaques, is formed by 2 weeks, is mature by 3 months, and accounts for the absence of blistering of healed epidermis. All skin antigens tested (involucrin, filaggrin, laminin, collagens IV and VII, fibronectin, and chondroitin-sulfate) were expressed by 16 days after grafting. This cultured skin analogue provides an experimental alternative to split-thickness skin graft that develops histiotypic markers of skin anatomy and antigen expression after wound closure.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8446717     DOI: 10.1097/00006534-199304000-00010

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  11 in total

1.  Development of microfabricated dermal epidermal regenerative matrices to evaluate the role of cellular microenvironments on epidermal morphogenesis.

Authors:  Katie A Bush; George D Pins
Journal:  Tissue Eng Part A       Date:  2012-07-30       Impact factor: 3.845

2.  Cultured skin substitutes reduce donor skin harvesting for closure of excised, full-thickness burns.

Authors:  Steven T Boyce; Richard J Kagan; Kevin P Yakuboff; Nicholas A Meyer; Mary T Rieman; David G Greenhalgh; Glenn D Warden
Journal:  Ann Surg       Date:  2002-02       Impact factor: 12.969

3.  Human dermal microvascular endothelial cells form vascular analogs in cultured skin substitutes after grafting to athymic mice.

Authors:  Dorothy M Supp; Kaila Wilson-Landy; Steven T Boyce
Journal:  FASEB J       Date:  2002-06       Impact factor: 5.191

Review 4.  Skin substitutes from cultured cells and collagen-GAG polymers.

Authors:  S T Boyce
Journal:  Med Biol Eng Comput       Date:  1998-11       Impact factor: 2.602

Review 5.  Burns (Part 2). Tops and flops using cultured epithelial autografts in children.

Authors:  M Meuli; M Raghunath
Journal:  Pediatr Surg Int       Date:  1997-09       Impact factor: 1.827

6.  Genomic Reprogramming and Skin-Like Maturation of Engineered Human Skin Substitutes.

Authors:  Dorothy M Supp
Journal:  Adv Wound Care (New Rochelle)       Date:  2012-04       Impact factor: 4.730

7.  Attachment of an aminoglycoside, amikacin, to implantable collagen for local delivery in wounds.

Authors:  S T Boyce; A P Supp; G D Warden; I A Holder
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

8.  Comparative assessment of cultured skin substitutes and native skin autograft for treatment of full-thickness burns.

Authors:  S T Boyce; M J Goretsky; D G Greenhalgh; R J Kagan; M T Rieman; G D Warden
Journal:  Ann Surg       Date:  1995-12       Impact factor: 12.969

9.  Noncytotoxic combinations of topical antimicrobial agents for use with cultured skin substitutes.

Authors:  S T Boyce; G D Warden; I A Holder
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

Review 10.  Tissue engineering and cell based therapies, from the bench to the clinic: the potential to replace, repair and regenerate.

Authors:  William L Fodor
Journal:  Reprod Biol Endocrinol       Date:  2003-11-13       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.